Azenta, Inc. — Filing Summary
Filing mismatch: The provided Form 10-K is for Brooks Automation, Inc., not Azenta, Inc. (the company’s later name). It covers the fiscal year ended September 30, 2016, including fourth-quarter results.
Business Context and Reporting Period
Brooks provided automation, cryogenic and sample-management solutions through two reportable segments: Brooks Semiconductor Solutions Group and Brooks Life Science Systems. Semiconductor-related activities represented approximately 81% of fiscal 2016 revenue and life-science activities approximately 19%.
The company reorganized its reporting structure from three segments to two during fiscal 2016. Prior-period segment information was reclassified to conform to the new presentation. BioStorage Technologies was acquired on November 30, 2015 and was included in results from the acquisition date.
Key Financial Metrics
| Metric | Fiscal 2016 | Fiscal 2015 | Change |
|---|---|---|---|
| Revenue | $560.3 million | $552.7 million | Up 1.4% |
| Gross profit | $198.1 million | $189.1 million | Up $9.0 million |
| Gross margin | 35.4% | 34.2% | Up 1.2 percentage points |
| Operating income | $4.2 million | $16.9 million | Down $12.7 million |
| Net income attributable to Brooks | $(69.5) million | $14.2 million | Declined $83.7 million |
| Diluted EPS | $(1.01) | $0.21 | Declined $1.22 |
| Operating cash flow | $39.5 million | $43.7 million | Down $4.2 million |
| Capital expenditures | $12.8 million | $16.1 million | Down $3.3 million |
- Fourth-quarter revenue was $157.6 million, gross profit was $56.6 million, operating income was $10.4 million and net income was $10.5 million.
- Semiconductor Solutions revenue was $452.2 million, down from $484.6 million. Segment operating income was $37.9 million versus $49.7 million.
- Life Science Systems revenue was $108.1 million, up from $68.1 million. Segment operating loss improved to $6.5 million from $19.6 million.
- Products generated $421.8 million of revenue and services generated $138.5 million. Services increased materially, primarily reflecting BioStorage-related activity.
- Cash, cash equivalents and marketable securities totaled $91.2 million at September 30, 2016, versus $214.0 million at the prior year-end.
- Working capital was $94.4 million. Total assets were $685.9 million and total equity was $553.7 million.
- The company had no borrowings outstanding under its $75.0 million senior secured revolving credit facility and reported approximately $57.8 million of borrowing availability.
- Annual dividends declared were $0.40 per share; $27.5 million of dividends were paid during fiscal 2016.
Material Changes Versus the Prior Comparable Period
- BioStorage contributed $44.6 million of fiscal 2016 revenue and increased Life Science Systems revenue by $40.0 million overall. The acquisition cost $125.2 million, net of cash acquired.
- Semiconductor revenue declined because of a cyclical downturn, including lower robotic automation, cryogenic pump, service and repair revenue. Contamination-control revenue increased.
- Foreign exchange reduced revenue by approximately $4.4 million.
- Royalty revenue declined to $8.7 million from $11.6 million. Patent expirations are expected to reduce annual revenue by approximately $12 million in future periods.
- The company exited an atmospheric-robot distribution arrangement, reducing fiscal 2016 revenue by approximately $5 million and expected to reduce annual revenue by approximately $29 million.
- Operating expenses increased by $21.6 million, including higher selling, general and administrative costs from the BioStorage acquisition and $12.0 million of restructuring charges.
- Life Science Systems gross margin improved to 36.1% from 26.0%, while Semiconductor Solutions gross margin declined slightly to 35.2% from 35.4%.
- The company recorded a $79.3 million additional valuation allowance against U.S. deferred tax assets, contributing to a $75.8 million income-tax provision and the reported net loss.
- Goodwill increased to $202.1 million from $121.4 million, primarily due to the BioStorage acquisition. Net intangible assets increased to $81.8 million from $55.4 million.
Guidance, Outlook, Risks and Unusual Items
The filing does not provide clear formal revenue or earnings guidance. Management expected continued growth in Life Science Systems from internally developed products, acquired businesses and sample-management services, while acknowledging substantial cyclicality and quarter-to-quarter volatility in semiconductor markets.
- Restructuring actions were expected to generate approximately $19.3 million of annual pretax cost savings, including $13.2 million from the company-wide program. The Jena, Germany repair-facility consolidation was expected to be completed by March 31, 2017.
- Semiconductor demand can fluctuate 10% to 20% sequentially, and downturns may cause operating losses. Competition, pricing pressure, customer concentration, technology changes and supply-chain interruptions remain significant risks.
- Approximately 63% of revenue was generated outside North America. Foreign currency exposure, Brexit-related uncertainty and international operational risks could affect revenue and margins.
- Goodwill and intangible assets are material to the balance sheet. The Polycold reporting unit had only a 12% fair-value cushion over carrying value at the latest assessment, increasing sensitivity to weaker forecasts or higher discount rates.
- The company had $104.6 million of other purchase commitments, primarily inventory commitments, and $5.9 million of accrued restructuring costs expected to be paid in fiscal 2017.
- Approximately 877,427 shares issued under the employee stock purchase plan may not have been registered on Form S-8. Potential rescission payments were estimated at up to approximately $950,000, including statutory interest.
- On November 28, 2016, after year-end, the company acquired Cool Lab, LLC for approximately $5 million in cash plus non-cash consideration with a carrying value of $9.1 million. Purchase accounting was incomplete at the filing date.
Most Important Facts to Verify
- Confirm that the intended issuer is Brooks Automation, Inc. rather than Azenta, Inc., and that the intended period is fiscal year 2016 rather than a standalone fourth quarter.
- Assess whether the $79.3 million deferred-tax valuation allowance is non-cash and the conditions required for any future reversal.
- Evaluate BioStorage integration, recurring service revenue, profitability and the remaining preliminary purchase-price allocation.
- Test the sustainability of the improved Life Science Systems margin and the expected restructuring savings.
- Assess semiconductor-cycle exposure, patent royalty expirations and the anticipated $29 million annual revenue reduction from the strategic exit.
- Review Polycold goodwill sensitivity, including the effect of lower revenue, margins or higher discount rates.
- Verify liquidity after the BioStorage acquisition, dividend payments, contractual commitments and the borrowing-base limitations on the revolving facility.
- Review the employee stock purchase plan registration issue, potential rescission exposure and any regulatory consequences.